|Articles|January 18, 2002
CDER News 12/31/01 through 1/2/02
Author(s)BioPharm International Editors
Original manufacturing supplements, original efficacy supplements, original and resubmitted NDAs, and new and generic drug approvals.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
2
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
3
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
4
Developing Next-Gen Cell Lines Using Targeted Integration
5
